
The landscape of COVID vaccines continues to evolve as new variants emerge, requiring updated formulas and targeted booster strategies. COVID vaccines 2025–2026, including Moderna mNEXSPIKE, Pfizer-BioNTech, and Novavax, focus on the JN.1 lineage and KP.2 variants, aiming to protect all age groups from severe illness, hospitalization, and death.
Booster shots remain a key component of maintaining immunity, particularly for older adults, immunocompromised individuals, and those at high risk during the respiratory virus season. Understanding vaccine effectiveness, timing, and the latest recommendations allows individuals to make informed decisions that maximize protection while minimizing risks.